Market closedNon-fractional

Immunic/IMUX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Immunic

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Ticker

IMUX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

New York, United States

Employees

80
Website
imux.com

Immunic Metrics

BasicAdvanced
$97M
Market cap
-
P/E ratio
-$1.70
EPS
1.93
Beta
-
Dividend rate
$97M
1.93
5.094
4.902
0.518
1.352
-56.24%
-112.05%
1.17
1.17
-0.825
-51.50%
-23.81%

What the Analysts think about Immunic

Analyst Ratings

Majority rating from 5 analysts.
Buy

Immunic Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$30M
37.21%
Profit margin
0.00%
NaN%

Immunic Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 15.38%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.54
-$0.51
-$0.48
-$0.30
-
Expected
-$0.52
-$0.55
-$0.51
-$0.26
-$0.23
Surprise
3.05%
-6.85%
-6.48%
15.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Immunic stock?

Immunic (IMUX) has a market cap of $97M as of July 06, 2024.

What is the P/E ratio for Immunic stock?

The price to earnings (P/E) ratio for Immunic (IMUX) stock is 0 as of July 06, 2024.

Does Immunic stock pay dividends?

No, Immunic (IMUX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Immunic dividend payment date?

Immunic (IMUX) stock does not pay dividends to its shareholders.

What is the beta indicator for Immunic?

Immunic (IMUX) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Immunic stock

Buy or sell Immunic stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing